Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...

Alongside record profits, USDT issuer Tether also reported Friday it now holds over $143 billion in reserve assets to back ...

All else equal, this would increase gasoline prices, which in most of the country have averaged $3 per gallon for the past ...

Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...

In a report released yesterday, Brett Knoblauch from Cantor Fitzgerald maintained a Buy rating on Cipher Mining (CIFR – Research Report), with ...

Cantor Fitzgerald analyst Thomas Blakey reiterated a Hold rating on Atlassian (TEAM – Research Report) yesterday and set a price target of ...